Silencing tau to treat early Alzheimer’s disease

An antisense oligonucleotide therapy substantially reduced tau expression in a phase 1b trial; whether this translates to clinical improvement remains to be seen, but it could have far-reaching implications for neurodegenerative diseases more broadly.

Saved in:

Bibliographic Details
Published in	Nature medicine Vol. 29; no. 6; pp. 1320 - 1321
Main Authors	Ljubenkov, Peter A., Rabinovici, Gil D.
Format	Journal Article
Language	English
Published	New York Nature Publishing Group US 01.06.2023 Nature Publishing Group
Subjects	Alzheimer's disease Antisense oligonucleotides Antisense therapy Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research Charitable foundations Clinical outcomes Clinical trials Dementia Infectious Diseases Medical research Metabolic Diseases Molecular Medicine Monoclonal antibodies Neurodegeneration Neurodegenerative diseases Neurosciences News & Views news-and-views Pathology Protein synthesis Proteins Tau protein
Online Access	Get full text
ISSN	1078-8956 1546-170X 1546-170X
DOI	10.1038/s41591-023-02357-w

Cover

More Information
Summary:	An antisense oligonucleotide therapy substantially reduced tau expression in a phase 1b trial; whether this translates to clinical improvement remains to be seen, but it could have far-reaching implications for neurodegenerative diseases more broadly.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1078-8956 1546-170X 1546-170X
DOI:	10.1038/s41591-023-02357-w